Redefining fatty liver disease classification in 2020

Saved in:
Bibliographic Details
Published inLiver international Vol. 40; no. 5; pp. 1016 - 1017
Main Authors Valenti, Luca, Pelusi, Serena
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2020
Subjects
diabetes
Fatty liver
fatty liver disease
genetics
Liver diseases
metabolism
steatosis
metabolism
genetics
diabetes
steatosis
fatty liver disease
Online AccessGet full text

Cover

More Information
Bibliography:Funding information
LV reports having received during the last 5 years speaking fees from MSD, Gilead, AlfaSigma, AbbVie, having served as a consultant of: Gilead, Pfizer, Astra Zeneca, Novo Nordisk, Diatech Pharmacogenetics and Intercept, and having received research grants from: Gilead.
SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-3
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14430